If you are still waiting for manufacturer restrictions on contract pharmacies to get reversed, stop waiting. The legal challenges have largely failed, HRSA enforcement has been inconsistent, and more manufacturers are adding restrictions every quarter. The contract pharmacy model that existed in 2020 is not coming back. Here is how to operate in the world that actually exists.
The Current Landscape
As of mid-2026, over 30 manufacturers have imposed some form of contract pharmacy limitation. The common requirement is that covered entities submit claims-level data through a designated third-party platform — usually 340B ESP — before the manufacturer will honor 340B pricing at contract pharmacies. Some manufacturers have gone further, limiting contract pharmacy arrangements to one per covered entity.
The financial impact varies by organization, but the pattern is clear: contract pharmacy savings on restricted manufacturers have dropped 50 to 80 percent for most covered entities. The drugs that generated the largest spreads — specialty medications, branded injectables — are disproportionately affected because their manufacturers were the first to impose restrictions.
The Data Submission Decision
You have two choices with restricted manufacturers: submit the claims data they are requesting, or forgo 340B pricing at contract pharmacies for those drugs. There is no third option that works at scale.
Most covered entities should submit the data. The privacy and administrative concerns are real but manageable. The data flows through a third-party intermediary, it is limited to claims information the manufacturer could arguably access through other channels, and the alternative — losing the savings entirely — is worse for your patients.
If you are not currently submitting to 340B ESP or a similar platform, start now. The registration process takes two to four weeks, and there is often a backlog of retroactive claims that can be recovered once you are enrolled.
Strengthen Your In-House Pharmacy
The strategic response to contract pharmacy restrictions is not better contract pharmacy management — it is less dependence on contract pharmacies altogether. Manufacturer restrictions do not apply to in-house pharmacies. Every prescription you fill at your own pharmacy captures 340B savings without data submission requirements, without TPA fees, and without the risk of further manufacturer restrictions.
If you are an FQHC without an in-house pharmacy, the business case for building one has never been stronger. If you have one but it captures less than 80 percent of eligible prescriptions, that gap is your highest-ROI project.
Renegotiate Your Contract Pharmacy Agreements
Most contract pharmacy agreements were written when the savings were larger and the administrative burden was lower. Review your agreements now. Are you paying dispensing fees that made sense at higher volumes but no longer justify the arrangement? Are there contract pharmacies that capture fewer than 50 prescriptions per month? Those arrangements cost more in oversight and compliance than they generate in savings.
Consolidate to your highest-performing contract pharmacy locations, renegotiate the fee structure to reflect current economics, and redirect the administrative time you were spending on underperforming sites to strengthening your in-house capture rate.
Plan for More Restrictions, Not Fewer
Every indication suggests that manufacturer restrictions will continue expanding. Build your 340B program on the assumption that contract pharmacy savings will be 30 to 50 percent lower than historical levels. If that assumption turns out to be wrong, you will have a pleasant surprise. If it turns out to be right, you will be the organization that planned for it instead of reacting to it.